Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial

Fuda Cancer Hospital, Guangzhou1 个研究点分布在 1 个国家开始时间: 2015年5月20日最近更新: 2021年9月9日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方
试验地点: 1

研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.

详细描述

By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for pancreatic cancer.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Karnofsky performance status >60
•Diagnosis of pancreatic cancer based on histology or the current accepted radiological measures.
•Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
•Will receive interventional therapy
•Life expectancy: Greater than 3 months
•Patients' routine blood test, liver function and kidney function have no obvious abnormalities
•Ability to understand the study protocol and a willingness to sign a written informed consent document

排除标准

•Patients with other primary tumor except pancreatic cancer
•History of coagulation disorders or anemia

研究者

发起方

Fuda Cancer Hospital, Guangzhou

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

1 期

Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung CarcinomaLung Cancer

NCT02449122Fuda Cancer Hospital, Guangzhou60

已完成

1 期

Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver CarcinomaLiver Cancer

NCT02449109Fuda Cancer Hospital, Guangzhou60

已完成

3 期

Evaluation of the Efficacy and Safety of Nano-S1COVID-19 Pneumonia

NCT05822180General Administration of Military Health, Tunisia116

已完成

1 期

Evaluation of NanoDoce® in Participants With Urothelial CarcinomaBladder CancerUrothelial CarcinomaUrinary Bladder NeoplasmUrinary Bladder CancerUrogenital NeoplasmsUrologic NeoplasmsUrologic CancerMalignant Tumor of the Urinary BladderCancer of the Bladder

NCT03636256NanOlogy, LLC36

已完成

不适用

Evaluate the Efficacy and Safety of the Digital Therapeutics Repeech for the Post-Stroke Dysarthria.Post-stroke Dysarthria

NCT06670014HAII corp.ltd108